European Journal of Heart Failure最新文献

{"title":"Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.","authors":"Marianna Adamo,Matteo Pagnesi,Ovidiu Chioncel,Antoni Bayes-Genis,Magdy Abdelhamid,Elena-Laura Antohi,Chiara Bucciarelli-Ducci,Alaide Chieffo,Bernard Cosyns,Martine Gilard,Julia Grapsa,Arántxa González,Finn Gustafsson,Bernard Iung,Michael Joner,Nicole Karam,Lars H Lund,Francesco Maisano,Brenda Moura,Fabien Praz,Tanja K Rudolph,Anna Sannino,Gianluigi Savarese,Carlo Gabriele Tocchetti,Vanessa P M Van Empel,Maurizio Volterrani,Stephan Windecker,Piotr Ponikowski,Giuseppe M C Rosano,Emanuele Barbato,Marco Metra","doi":"10.1002/ejhf.70023","DOIUrl":"https://doi.org/10.1002/ejhf.70023","url":null,"abstract":"Aortic stenosis (AS) is common and can cause heart failure (HF) or contribute to the progression of pre-existing HF. The management of patients with concomitant AS and HF poses specific clinical challenges. Optimization of guideline-directed medical therapy for HF may be difficult in patients with AS, especially in case of reduced left ventricular ejection fraction. Transcatheter or surgical aortic valve replacement (AVR) is the evidence-based treatment of choice for patients with severe AS and HF. However, advanced cardiac damage, concomitant conditions that can cause HF in addition to AS, as well as some procedure-related factors, may contribute to persistence or worsening of HF after AVR. A multidisciplinary management involving an HF specialist is crucial in this setting and should include a dedicated pre-procedural HF and AS assessment, as well as a careful post-procedural follow-up, including monitoring of HF status. The aim of this clinical consensus statement is to summarize current knowledge on AS and HF, with a focus on pre-procedural and post-procedural management of patients with HF undergoing AVR.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"30 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145059039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of genotype-phenotype associations on prognosis in dilated cardiomyopathy.","authors":"Sophie L V M Stroeks,Ping Wang,Marco Merlo,Steven Muller,Alessia Paldino,Nerea Mora-Ayestaran,Max Jason,Matteo Dal Ferro,Carola Pio Loca,Fernando Dominguez,Esther Gonzalez-Lopez,Arthur van den Wijngaard,Max F G H M Venner,Maurits Sikking,Michiel Minten,Bastien Nihant,Nina Beelen,Sharon Graw,Kristen Medo,Bart de Koning,Matthew Taylor,J Peter van Tintelen,Luisa Mestroni,Gianfranco Sinagra,Anneline S J M Te Riele,Pablo Garcia-Pavia,Stephane Heymans,Job A J Verdonschot","doi":"10.1002/ejhf.70040","DOIUrl":"https://doi.org/10.1002/ejhf.70040","url":null,"abstract":"AIMSDilated cardiomyopathy (DCM) has a monogenic aetiology in up to 40% of patients. Understanding the spectrum of genotype-phenotype associations in DCM is crucial for risk stratification and personalized treatment. We aimed to (i) characterize genotype-specific features, (ii) evaluate whether phenotype-based clustering reflects underlying genotype, and (iii) compare the prognostic value of genotype- versus phenotype-based approaches.METHODS AND RESULTSA multicentre cohort of 534 DCM patients with a (likely) pathogenic variant were grouped by genotype (genotype-first approach) and clustered by clinical phenotype (phenotype-first approach). We compared clinical characteristics, identified genotype-phenotype associations, and evaluated outcomes, including all-cause mortality, heart failure hospitalization, heart transplantation, and malignant ventricular arrhythmias. Using the genotype-first approach, significant genotype-phenotype associations were found for 10 genes. FLNC, LMNA, DSP, and PLN variants were linked to arrhythmias. BAG3, TNNT2, DMD, and TTN were associated with increased cardiac volumes and decreased left ventricular ejection fraction (LVEF). Clustering identified four phenotypic clusters: (1) young, moderately reduced LVEF; (2) arrhythmias, moderate reduced LVEF; (3) low LVEF; (4) arrhythmias, low LVEF. There were no clear correlations between phenotypic clusters and genotype. The genotype-first approach showed that LMNA, FLNC, and BAG3 variants had the highest risk for heart failure and arrhythmogenic adverse outcomes. The phenotype-first approach indicated that clusters 3 and 4 were associated with the worst prognosis. Overall, genotype was the strongest predictor of outcome.CONCLUSIONSPatients with a genetic form of DCM exhibit clinical and genetic heterogeneity. Genotype-based risk stratification is more accurate compared to a phenotype-first approach, highlighting the importance of broad genetic screening among patients with DCM. Additionally, gene-specific risk prediction should become more prominent in current guidelines on management of genetic DCM patients.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"69 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.","authors":"Kalliopi Keramida,Teresa Lopez-Fernandez,Markus S Anker,Mark C Petrie,Pietro Ameri,Lisa J Anderson,Jutta Bergler-Klein,Anita Deswal,Dimitrios Farmakis,Borja Ibañez,Carolyn S P Lam,Ninian N Lang,Alexander R Lyon,Mariana Mirabel,Brenda Moura,Walter J Paulus,Amina Rakisheva,Gianluigi Savarese,Michele Senni,Carlo Gabriele Tocchetti,Marco Metra,Gerasimos Filippatos","doi":"10.1002/ejhf.70005","DOIUrl":"https://doi.org/10.1002/ejhf.70005","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown. This statement underscores the imperative need to include HFpEF in the cardiotoxicities identified during or after anticancer treatments. It also highlights the prognostic value of pre-existing HFpEF for periprocedural and cardiotoxicity risk and it discusses the challenges in the diagnosis and treatment of HFpEF in cancer patients. It also explores the aetiologic role of anticancer therapies (chemotherapy, targeted and hormonal therapies and radiotherapy) in the pathogenesis of HFpEF. Special emphasis is given on the importance of considering HFpEF from cancer diagnosis throughout treatment and survivorship and provides useful insights for cardiologists and oncologists in the monitoring and management of these patients. Finally, it highlights the key gaps in current knowledge that require further investigation through well-designed research trials to enhance our understanding and improve clinical outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"36 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes.","authors":"Benedikt N Beer,Lina Benson,Christian Basile,Benedikt Schrage,Peter Moritz Becher,Stefan Blankenberg,Paulus Kirchhof,Barna Szabó-Söderberg,Marco Metra,Anne Lindberg,Egidio Imbalzano,Giuseppe M C Rosano,Patric Karlström,Peter G M Mol,Raffaele Scorza,Lars H Lund,Felix Lindberg,Gianluigi Savarese","doi":"10.1002/ejhf.70046","DOIUrl":"https://doi.org/10.1002/ejhf.70046","url":null,"abstract":"AIMSPatients with heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) are poorly represented in HFrEF trials testing beta-blockers. We assessed cardiovascular effectiveness and respiratory safety of beta-blockers in these patients.METHODS AND RESULTSPatients with HFrEF and COPD in the Swedish HF Registry (2006-2023) were included. Overlap-weighted models were used to assess associations between beta-blocker use and 5-year risk of outcomes, with cardiovascular death/total hospitalizations for HF (HHF) representing the primary cardiovascular effectiveness outcome, and total severe COPD exacerbations being the primary respiratory safety outcome. Of 5084 patients with HFrEF and COPD, median age was 75 years (interquartile range [IQR] 69-81), 68.3% were male, 36.9% were in GOLD group E, 91.5% used beta-blockers. Over a median follow-up of 2.5 years (IQR 1.0-4.8), beta-blocker users had lower crude risk of cardiovascular death/total HHF (rate ratio [RR] 0.66, 95% confidence interval [CI] 0.56-0.78) and total severe COPD exacerbations (RR 0.75, 95% CI 0.60-0.93). After overlap weighting, beta-blocker use was independently associated with lower risk of cardiovascular death/total HHF (RR 0.74, 95% CI 0.58-0.96) but not total severe COPD exacerbations (RR 0.99, 95% CI 0.73-1.35). These associations were consistent across subgroups (including GOLD groups), except for the greater magnitude of the association with lower risk of cardiovascular death/total HHF in patients with left ventricular ejection fraction <30% (p for interaction = 0.004). Falsification analyses suggested no influence from residual confounding.CONCLUSIONSIn patients with HFrEF and COPD, beta-blocker use was associated with lower risk of cardiovascular death/total HHF, without evidence of safety concerns for COPD exacerbations.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct blood volume and left ventricular adaptation to severe obesity in middle-aged adults at risk for heart failure.","authors":"Joseph Campain,Denis J Wakeham,Katrin Dias,James P MacNamara,Mitchel Samels,Erin J Howden,Graeme Carrick-Ranson,Michinari Hieda,Benjamin D Levine,Satyam Sarma,Christopher M Hearon","doi":"10.1002/ejhf.70037","DOIUrl":"https://doi.org/10.1002/ejhf.70037","url":null,"abstract":"AIMSObesity is commonly hypothesized to lead to the development of heart failure (HF) in part due to increases in blood volume (BV) and left ventricular (LV) remodelling. Whether adiposity and obesity severity are associated with BV expansion and subsequent LV remodelling in middle-aged individuals at increased risk (IR) prior to the onset of HF is unknown.METHODS AND RESULTSWe analysed data from 96 middle-aged (40-64 years) non-obese (25.8 [23.6-28.6] kg/m2) controls (CON) and 126 IR middle-aged adults (elevated cardiac biomarkers plus established risk factors). IR adults were stratified based upon body mass index class: (1) <30 kg/m2, IRNon-Obese (n = 28, 28.2 [24.6-29.9] kg/m2); (2) Class I >30-35 kg/m2, IRClass-I (n = 39, 33 [31.9-33.6] kg/m2); and, (3) Class II/III >35 kg/m2, IRClass-II/IIII (n = 59, 41.2 [37.1-43.8] kg/m2). BV (carbon monoxide rebreathing), body composition (hydrodensitometry or dual-energy X-ray absorptiometry), and LV structure and function (echocardiography) were assessed. Fat mass was independently associated with BV (β = 0.17, p < 0.001) which was independently associated with LV end-diastolic volume (LVEDV) index (β = 0.54, p < 0.001). BV was lower in CON (5046 ± 1123 ml) than all IR groups (IRNon-Obese: 5622 ± 1137; IRClass-I: 6033 ± 1237; IRClass-II/III: 6548 ± 1153 mL; all p < 0.05). IRClass-II/III had greater erythrocyte volume compared to CON (p < 0.005), even after normalization to fat-free mass (CON: 36.2 ± 4.6; IRClass-II/III: 39.9 ± 5.1 ml/kg fat-free mass; p < 0.001). Only IRClass-II/III had an enlarged LV end-diastolic volume when normalized to body surface area compared to both CON and IRNon-Obese (both, p < 0.05).CONCLUSIONSWhile lean mass is the primary determinant of BV, fat mass is independently associated with BV expansion and larger LVEDV. IR adults with class II/III obesity display distinct LV enlargement that is disproportionate to body size (i.e. LVEDV index) and may represent a physiologically distinct subgroup of obesity as opposed to a simple continuum of disease severity.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"13 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential therapeutic effects of warming on patients with heart failure.","authors":"Parin Shah,Terak Bekfani,Pawel Rubis,Andrew L Clark,John G F Cleland","doi":"10.1002/ejhf.70011","DOIUrl":"https://doi.org/10.1002/ejhf.70011","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"56 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC-HF II molecular substudy.","authors":"Mohamad F Barakat,Nelson Amaral,Daniel Brayson,George Amin-Youssef,Huda Abu-Own,Salma Ayis,Francesco Papalia,Fadi Jouhra,Adam Nabeebaccus,Mark Monaghan,Gerry Carr-White,Alison Sleigh,Geoffrey Charles-Edwards,Ajay M Shah,Graham J Kemp,Andrew J Murray,Darlington O Okonko","doi":"10.1002/ejhf.70028","DOIUrl":"https://doi.org/10.1002/ejhf.70028","url":null,"abstract":"AIMSSkeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion. This molecular substudy of the FERRIC-HF II trial tested the hypothesis that ferric derisomaltose (FDI) would improve electron transport chain activity, given its high dependence on iron-sulfur clusters which facilitate electron transfer during oxidative phosphorylation.METHODS AND RESULTSVastus lateralis skeletal muscle biopsies were taken before and 2 weeks after randomization. Mitochondrial complex I, II, and I&II respiration were quantified with respirometry of permeabilized fresh skeletal muscle biopsies. Net respiratory capacities, reflecting respiration that is truly available for adenosine triphosphate generation, were calculated by subtracting non-phosphorylating LEAK respiration. Complex I-V and myoglobin protein levels, and skeletal muscle fibre type composition were assayed. Patients randomised to FDI (n = 21) or placebo (n = 19) were similar (age 66 ± 13 years, 73% men, left ventricular ejection fraction 37 ± 8%, 48% New York Heart Association class III, 50% diabetic). After 2 weeks, total complex I-linked respiration (0.33 [interquartile range 0.24-0.37] vs. 0.19 [0.06-0.27] nmol/min/mg, p = 0.03) and net complex I-linked respiration (0.21 [0.16-0.24] vs. 0.11 [0.04-0.16] nmol/min/mg, p = 0.01) were higher in patients allocated to FDI. There was no intergroup difference in other respiratory states, in mitochondrial abundance as reflected by complex I-V protein levels, and in skeletal muscle myoglobin and oxidative fibre type content.CONCLUSIONSIron repletion induces an early, selective, and potentially direct enhancement of mitochondrial complex I-dependent respiration in the skeletal muscle of heart failure patients. This could be harnessed to optimize repletion protocols to maximize patient benefits.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'.","authors":"Mohammad A Almesned,Bart J van Essen,Adriaan A Voors,Erik Lipsic","doi":"10.1002/ejhf.70044","DOIUrl":"https://doi.org/10.1002/ejhf.70044","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"16 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'.","authors":"Soufiane Nassiri,Geert H D Voordes,M Louis Handoko,Adriaan A Voors","doi":"10.1002/ejhf.70038","DOIUrl":"https://doi.org/10.1002/ejhf.70038","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"163 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.","authors":"John W Ostrominski,Brian L Claggett,Akshay S Desai,Pardeep S Jhund,Carolyn S P Lam,Michele Senni,Sanjiv J Shah,Adriaan A Voors,Faiez Zannad,Bertram Pitt,Katja Rohwedder,Meike Brinker,Patrick Schloemer,John J V McMurray,Scott D Solomon,Muthiah Vaduganathan","doi":"10.1002/ejhf.70034","DOIUrl":"https://doi.org/10.1002/ejhf.70034","url":null,"abstract":"AIMSThe estimated glucose disposal rate (eGDR) is a simple, non-invasive measure of insulin resistance. In this exploratory analysis of FINEARTS-HF, we evaluated whether lower eGDR, reflecting greater insulin resistance, is associated with adverse outcomes in heart failure (HF).METHODS AND RESULTSThe eGDR was calculated at baseline using waist circumference, glycated haemoglobin, and hypertension status. Clinical outcomes and treatment effects of finerenone according to baseline eGDR (<median or ≥median) were evaluated. Among 5851 (98%) participants with a calculable eGDR (median [interquartile range] 5.1 [3.9-6.3] mg/kg/min), lower eGDR was associated with greater albuminuria and worse HF-related health status at baseline. Compared with participants with eGDR ≥5.1 mg/kg/min, those with eGDR <5.1 mg/kg/min experienced a 63% higher rate of cardiovascular death and total HF events (adjusted rate ratio [aRR] 1.63; 95% confidence interval [CI] 1.41-1.87; p < 0.001). Similar findings were observed in participants with diabetes (aRR 1.72; 95% CI 1.40-2.12) and without diabetes (aRR 1.34; 95% CI 1.07-1.68; pinteraction = 0.06). Lower baseline eGDR was additionally associated with a higher rate of vascular events, kidney outcomes, new-onset diabetes, and all-cause death. Treatment benefits of finerenone on cardiovascular death and total HF events (pinteraction = 0.64) and new-onset diabetes (pinteraction = 0.36) appeared consistent irrespective of baseline eGDR category. Baseline eGDR category did not modify the safety profile of finerenone.CONCLUSIONSThe eGDR, a validated measure of insulin resistance, was associated with a wide range of cardiovascular, kidney, and metabolic outcomes in patients with HF, including among those without diabetes. Finerenone reduced risk of cardiovascular outcomes and new-onset diabetes, irrespective of baseline insulin resistance.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov NCT04435626.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"103 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}